Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 5, 2007, Pages 346-353

  Lipton, Allan ^a   Cook, Richard J ^b   Coleman, Robert E ^c   Smith, Matthew R ^d   Major, Pierre ^e   Terpos, Evangelos ^f   Berenson, James R ^g  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^g INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

Bone markers; Telopeptides; Zoledronic acid

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DEOXYPYRIDINOLINE; HYDROXYPROLINE; IBANDRONIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PYRIDINOLINE; SIALOPROTEIN; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FRACTURE; HUMAN; MORBIDITY; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; X RAY ANALYSIS;

EID: 34248143552     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.011     Document Type: Review

References (72)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(suppl 4):14-27.
2. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991; 88:62-66.
3. Roux C, Ravaud P, Cohen-Solal M, et al, Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15:41-49.
4. Taube T, Beneton MN, McCloskey EV, et al. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49:192-198.
5. Valentin-Opran A, Charhon SA, Meunier PJ, et al. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982; 52:601-610.
6. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19:3562-3571.
7. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004; 125:38-41.
8. Horwood NJ, Elliott J, Martin TJ, et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139:4743-4746.
9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
10. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
11. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527-3533.
12. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98:11581-11586.
13. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98:2269-2271.
14. Dizdar O, Barista I, Kalyoncu U, et al. Biochemical markers of bone turnover in the diagnosis of myeloma bone disease. J Clin Oncol 2005; 23(16 suppl):585s (Abstract #6600).
15. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126:686-689.
16. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88:5059-5075.
17. Woitge HW, Pecherstorfer M, Li Y, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14:792-801.
18. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94:2521-2533.
19. Delmas PD, Schlemmer A, Gineyts E, et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6:639-644.
20. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine 1997; 22(suppl):17S-24S.
21. Eyre DR, Dickson IR, Van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988; 252:495-500.
22. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998; 22:181-187.
23. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22:289-331.
24. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34:2021-2026.
25. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41:1489-1494.
26. Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999; 80:221-228.
27. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27:187-192; discussion, 193-196.
28. Carlson K, Larsson A, Simonsson B, et al. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999; 62:300-306.
29. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
30. Fonseca R, Trendle MC, Leong T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000; 109:24-29.
31. Abildgaard N, Brixen K, Kristensen JE, et al. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003; 120:235-242.
32. Terpos E, Politou M, Szydlo R, et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18:1420-1426.
33. Alexandrakis MG, Passam FH, Malliaraki N, et al. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002; 325:51-57.
34. Romas NA, Rose NR, Tannenbaum M. Acid phosphatase: new developments. Hum Pathol 1979; 10:501-512.
35. Yam LT. Clinical significance of the human acid phosphatases: a review. Am J Med 1974; 56:604-616.
36. Lau KH, Onishi T, Wergedal JE, et al. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 1987; 33:458-462.
37. Scarnecchia L, Minisola S, Pacitti MT, et al. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51:517-524.
38. Grano M, Mori G, Minielli V, et al. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000; 270:1097-1100.
39. Terpos E, de la Fuente J, Szydlo R, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003; 106:455-457.
40. Moss DW. Perspectives in alkaline phosphatase research. Clin Chem 1992; 38:2486-2492.
41. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999; 45:1359-1368.
42. De Leo V, Ditto A, la Marca A, et al. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int 2000; 66:263-267.
43. Eastell R, Peel NF, Hannon RA, et al. The effect of age on bone collagen turnover as assessed by pyridinium crosslinks and procollagen I C-terminal peptide. Osteoporos Int 1993; 3(suppl 1):100-101.
44. Cross NA, Hillman LS, Allen SH, et al. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 1995; 61:514-523.
45. Carlson K, Ljunghall S, Simonsson B, et al. Serum osteocalcin concentrations in patients with multiple myeloma - correlation with disease stage and survival. J Intern Med 1992; 231:133-137.
46. Mejjad O, Le Loet X, Basuyau JP, et al. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myelome (GERM). Eur J Haematol 1996; 56:30-34.
47. Corso A, Arcaini L, Mangiacavalli S, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001; 86:394-398.
48. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002; 69:37-42.
49. Jakob C, Zavrski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003; 9:3047-3051.
50. Samani KK, Brazier M, Mathiot C, et al. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Ann Hematol 2005; 84:19-24.
51. Yamamoto I, Morita R, Konishi J, et al. Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis - comparison with bone scintigraphy and other metabolic bone markers [in Japanese]. Kaku Igaku 1995; 32:501-510.
52. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000; 64:121-129.
53. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102:1064-1069.
54. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical ptactice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20:3719-3736.
55. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4:30-34.
56. Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001; 7:478-485.
57. Jagdev SP, Putohit P, Heatley S, et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001; 12:1433-1438.
58. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005; 31(suppl 3): 19-25.
59. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593-602.
60. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387.
61. Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 2003; 70:34-42.
62. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19:1969-1976.
63. Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000; 65:331-336.
64. Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20:2353-2359.
65. Lipton A, Hei Y, Coleman R, et al. Suppression of bone turnover mark ers by zoledronic acid and correlation with clinical outcome. J Clin Oncol 2005; 23(16 suppl):11s (Abstract #532).
66. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
67. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
68. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-2621.
69. Lipton A, Cook R, Coleman R, et al. Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors. Ann Oncol 2006; 17(suppl 9):ix254 (Abstract #870P).
70. Major P, Hirsh V, Lipton A, et al. Zoledronic acid may improve survival in lung cancer patients with high baseline bone marker levels. Ann Oncol 2006; 17(suppl 9):ix221 (Abstract #739PD).
71. Berenson J, Shirina N, Chen Y-M. Zoledronic acid is associated with a survival benefit in patients with multiple myeloma stratified by baseline bone alkaline phosphatase levels. Presented at: MASCC/ISOO 18th International Symposium; June 22-24, 2006; Toronto, Ontario, Canada. Abstract #1621.
72. Berenson JR, Shirina N, Chen Y-M, et al. Survival in patients with multiple myeloma receiving zoledronic acid: stratification by baseline bone alkaline phosphatase levels. J Clin Oncol 2006; 24(18 suppl):423s (Abstract #7505).